Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
  • 1

    Mackenzie JS, Gubler DJ, Petersen LR, 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10 (Suppl 12): 98–109.

    • Search Google Scholar
    • Export Citation
  • 2

    World Health Organization, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.

  • 3

    Halstead SB, 2002. Dengue. Curr Opin Infect Dis 15 :471–476.

  • 4

    Gubler DJ, 1998. Dengue and dengue haemorrhagic fever. Clin Microbiol Rev 11 :480–496.

  • 5

    Bhamarapravati N, Sutee Y, 2000. Live attenuated tetravalent dengue vaccine. Vaccine 18 (Suppl 2):44–47.

  • 6

    Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J, 2004. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22 :3563–3574.

    • Search Google Scholar
    • Export Citation
  • 7

    Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N, 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 :264–272.

    • Search Google Scholar
    • Export Citation
  • 8

    Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Reed G, Ennis FA, Rothman AL, Green S, 2005. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192 :510–519.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 1 1 1
Full Text Views 294 116 12
PDF Downloads 95 53 10
 
 
 
 
 
 
 
 
 
 
 

IMMUNE RESPONSE AND OCCURRENCE OF DENGUE INFECTION IN THAI CHILDREN THREE TO EIGHT YEARS AFTER VACCINATION WITH LIVE ATTENUATED TETRAVALENT DENGUE VACCINE

PORNTHEP CHANTHAVANICHDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by PORNTHEP CHANTHAVANICH in
Current site
Google Scholar
PubMedClose
,
CHRISTINE LUXEMBURGERDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by CHRISTINE LUXEMBURGER in
Current site
Google Scholar
PubMedClose
,
CHUKIAT SIRIVICHAYAKULDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by CHUKIAT SIRIVICHAYAKUL in
Current site
Google Scholar
PubMedClose
,
KESWADEE LAPPHRADepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by KESWADEE LAPPHRA in
Current site
Google Scholar
PubMedClose
,
KRISANA PENGSAADepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by KRISANA PENGSAA in
Current site
Google Scholar
PubMedClose
,
SUTEE YOKSANDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by SUTEE YOKSAN in
Current site
Google Scholar
PubMedClose
,
ARUNEE SABCHAREONDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by ARUNEE SABCHAREON in
Current site
Google Scholar
PubMedClose
, and
JEAN LANGDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

Search for other papers by JEAN LANG in
Current site
Google Scholar
PubMedClose
View More View Less
DOI:
https://doi.org/10.4269/ajtmh.2006.75.1.0750026
Volume/Issue:
Volume 75: Issue 1
Page(s):
26–28
Restricted access
Get Permissions

From 1992 to 1997, 140 Thai children 4–15 years of age received an investigational live attenuated tetravalent dengue vaccine (LATDV). These children were contacted 3–8 years later in 2001 to assess humoral immunity and investigate whether they were subsequently at higher risk of developing severe dengue. One hundred thirteen were successfully contacted and participated in this retrospective cohort study with two age- and address-matched controls per vaccinee. The number of vaccinated subjects with neutralizing antibodies increased compared with 3–8 years earlier, which was probably due to subsequent wild-type dengue infections. There were no excess hospitalizations for clinically suspected dengue fever (DF) or dengue hemorrhagic fever (DHF) in vaccinees (one with DF and three with DHF) compared with controls (14 with DHF). Results suggest that preexisting dengue antibodies induced by LATDV do not enhance dengue illness, and the use of the vaccine in a dengue-endemic area is safe.

Copyright:
Copyright 2006 The American Society of Tropical Medicine 2006
Received:
02 Aug 2005
|
Accepted:
23 Mar 2006
|
Published Online:
Jul 2006
Save